The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast growth factor 21 analog, designed to treat patients with biopsy-confirmed ...

The Swedish biotech hopes its precision therapy will help patients with advanced solid tumors who currently have few ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...

Axovia’s lead program AXV101 is an adeno-associated virus (AAV9)-based investigational gene therapy that aims to slow down or ...

Josh Gissing is Cluster Head (UK, Ireland & Nordics) for Biocon Biologics: a biosimilars company whose business model seeks ...

The French biotech company Nanobiotix announced today that it has dosed the first patient in the CONVERGE study, a Phase 2 ...

Diane Lacroix, Vice President of Clinical Data Management at eClinical Solutions, talks personalised medicine, data decisions ...

The oversubscribed Series C financing round will support the clinical development of in vivo CAR-T cells for oncology and ...

As Director of R&D at Sunflower Therapeutics, Laura Crowell works with a team developing biologic medicines and vaccines. She ...